Superior virological suppression with nevirapine/zidovudine/lamivudine versus abacavir/zidovudine/lamivudine without evidence of clinical benefit to 48 weeks: a randomised comparison in patients with low CD4 counts in Africa.

Abstract

600 HIV-infected patients in Uganda were treated with zidovudine/lamivudine plus either abacavir or nevirapine. Viral load, measured after 0, 24 and 48 weeks, was reduced in both groups but significantly more so in the nevirapine group; CD4 lymphocyte count, measured at 12-week intervals, was increased in both groups but siginificantly more so in the nevirapine group. Clinical events, although not very numerous in either group, showed a trend towards being less common in the abacavir group. Possible reasons for the inconsistent results are discussed.

Citation

14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, USA, 25-28 February 2007: Abstract 506.

Superior virological suppression with nevirapine/zidovudine/lamivudine versus abacavir/zidovudine/lamivudine without evidence of clinical benefit to 48 weeks: a randomised comparison in patients with low CD4 counts in Africa.

Help us improve GOV.UK

Don’t include personal or financial information like your National Insurance number or credit card details.